IP Group portfolio company Enterprise Therapeutics reveals positive cystic fibrosis trial results

IP Group PLC (LSE:IPO) told investors that its portfolio company Enterprise Therapeutics has reported positive Phase 2 trial results for ETD001, its lead candidate for cystic fibrosis, after the inhaled treatment achieved its primary efficacy outcome. The trial evaluated ETD001's efficacy, safety, tolerability and pharmacokinetics in the 10% of people with cystic fibrosis described as having the highest unmet medical need.